Vaginal treatment with solid state non ablative laser 1470 nm for vaginal atrophy in post menopausal women

Submitted: 16 June 2023
Accepted: 23 August 2023
Published: 28 September 2023
Abstract Views: 3150
PDF: 25
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

One of the most common menopausal symptoms is vaginal dryness. Menopausal sex hormone deficiency causes changes in the urogenital tract, where estrogens are the primary regulators of vaginal physiological functions. Many treatments have been developed over the years, but the majority of them are ineffective or have potential side effects. Actually, laser therapy has the highest efficacy with the fewest (or none) side effects. Thermal energy acting on the vaginal wall has been shown in studies to stimulate collagen synthesis, induce neovascularization, enrich the glycogen epithelium, improve vaginal lubrication, and treat urinary incontinence. However, not all lasers are created equal. The majority of published studies describe the data from CO2 laser therapy, Erbium laser therapy, and radiofrequency. Less is known about the new 1470 nm solid state laser. This is a retrospective study in which 16 women with vaginal dryness were treated with a 1470 nm solid state vaginal laser. All of the patients were cured of vaginal dryness with no pain, bleeding, scarring, or other side effects.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

(1) Portman DJ, Gass MLS. Genitourinary syndrome of menopause: New terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Menopause 2014;21:1063–1068. DOI: https://doi.org/10.1097/GME.0000000000000329
(2) Menopause society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902-904. DOI: https://doi.org/10.1097/GME.0b013e3182a122c2
(3) Angelou K, Grigoriadis T, Diakosavvas M, et al. The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus 2020;12:e7586. DOI: https://doi.org/10.7759/cureus.7586
(4) Kagan R, Kellogg-Spadt S, Parish SJ. Practical Treatment Considerations in the Management of Genitourinary Syndrome of Menopause. Drugs Aging 2019;36:897-908. DOI: https://doi.org/10.1007/s40266-019-00700-w
(5) US Food and Drug Administration. Statement from FDA Commissioner Scott Gottlieb, M.D., on efforts to safeguard women’s health from deceptive health claims and significant risks related to devices marketed for use in medical procedures for “vaginal rejuvenation.” News release. July 30, 2018. Accessed December 19, 2022. Available from: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims
(6) Lubián López DM. Management of genitourinary syndrome of menopause in breast cancer survivors: An update. World J Clin Oncol 2022;13:71-100. DOI: https://doi.org/10.5306/wjco.v13.i2.71
(7) El-Domyati M, Abd-El-Raheem T, Medhat W, et al. Multiple fractional erbium: yttrium-aluminum-garnet laser sessions for upper facial rejuvenation: clinical and histological implications and expectations. J Cosmetic Dermatol 2014;13:30–37. DOI: https://doi.org/10.1111/jocd.12079
(8) Tadir Y, Gaspar A, Lev-Sagie A, et al. Light and energy based therapeutics for genitourinary syndrome of menopause: consensus and controversies. Lasers Surg Med 2017;49:137–159. DOI: https://doi.org/10.1002/lsm.22637
(9) Mension E, Alonso I, Tortajada M, et al. Vaginal laser therapy for genitourinary syndrome of menopause - systematic review. Maturitas 2022;156:37-59. DOI: https://doi.org/10.1016/j.maturitas.2021.06.005
(10) Li B, Duan H, Chang Y, Wang S. Efficacy and safety of current therapies for genitourinary syndrome of menopause: A Bayesian network analysis of 29 randomized trials and 8311 patients. Pharmacol Res 2021;164:105360. DOI: https://doi.org/10.1016/j.phrs.2020.105360
(11) Franić D, Fistonić. Laser Therapy in the Treatment of Female Urinary Incontinence and Genitourinary Syndrome of Menopause: An Update. Biomed Res Int 2019;2019:1576359. DOI: https://doi.org/10.1155/2019/1576359
(12) Dodero D, Frascani F, Angelucci M, et al. .Solid State Vaginal Laser for the Treatment of Genitourinary Syndrome of Menopause: A Preliminar Report. Open J Obstet Gynecol 2018;8:113-121. DOI: https://doi.org/10.4236/ojog.2018.82015
(13) Dodero D, Frascani F, Angelucci M, et al. Histological Modifications of Postmenopausal Vaginal Mucosa after Regenerative Solid State Laser Treatment: A Multicenter Study. Int J Womens Health Wellness 2019;5:099. DOI: https://doi.org/10.23937/2474-1353/1510099

How to Cite

Mallozzi, M. (2023). Vaginal treatment with solid state non ablative laser 1470 nm for vaginal atrophy in post menopausal women. Laser Therapy, 30(1). https://doi.org/10.4081/ltj.2023.320